Cargando…
Positive expression of programmed death ligand-1 correlates with superior outcomes and might be a therapeutic target in primary pulmonary lymphoepithelioma-like carcinoma
BACKGROUND: Primary pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare subtype of non-small cell lung cancer (NSCLC), and no effective treatments have been defined for advanced disease. Programmed cell death-ligand 1 (PD-L1) is expressed in a group of cancers that may be suitable targets fo...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4474388/ https://www.ncbi.nlm.nih.gov/pubmed/26109869 http://dx.doi.org/10.2147/OTT.S84234 |
_version_ | 1782377263759622144 |
---|---|
author | Jiang, Li Wang, Liang Li, Peng-fei Zhang, Xin-ke Chen, Jie-wei Qiu, Hui-juan Wu, Xiao-dong Zhang, Bei |
author_facet | Jiang, Li Wang, Liang Li, Peng-fei Zhang, Xin-ke Chen, Jie-wei Qiu, Hui-juan Wu, Xiao-dong Zhang, Bei |
author_sort | Jiang, Li |
collection | PubMed |
description | BACKGROUND: Primary pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare subtype of non-small cell lung cancer (NSCLC), and no effective treatments have been defined for advanced disease. Programmed cell death-ligand 1 (PD-L1) is expressed in a group of cancers that may be suitable targets for specific immunotherapy. METHODS: This study investigated the expression and clinical value of PD-L1 in pulmonary LELC. Seventy-nine patients with pulmonary LELC were investigated. Paraffin-embedded tumor sections were stained with PD-L1 antibody. Correlations of PD-L1 expression with clinicopathologic parameters and outcomes were analyzed. RESULTS: Fifty patients (63.3%) were PD-L1 positive. The 3-year and 5-year progression-free survival (PFS) rate was 76.0% and 68.0%, respectively, and the 3-year and 5-year overall survival (OS) rate was 88.0% and 79.0%, respectively. Kaplan–Meier analysis revealed that patients with positive PD-L1 expression had longer PFS and OS than those with negative PD-L1 expression (P=0.019 and P=0.042, respectively). In a multivariate Cox regression model including age, tumor size, stage, and PD-L1 expression status, the latter three factors were found to be independent predictors of PFS (P=0.023, P=0.000, and P=0.009, respectively), but only stage was found to be an independent factor for OS (P=0.007), and PD-L1 expression status showed a trend to be independently correlated with OS (P=0.080). CONCLUSION: Our results showed that a large proportion of patients with pulmonary LELC had positive expression of PD-L1, supporting the potential use of anti-PD-1/PD-L1-targeted therapies in this distinct type of NSCLC. |
format | Online Article Text |
id | pubmed-4474388 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-44743882015-06-24 Positive expression of programmed death ligand-1 correlates with superior outcomes and might be a therapeutic target in primary pulmonary lymphoepithelioma-like carcinoma Jiang, Li Wang, Liang Li, Peng-fei Zhang, Xin-ke Chen, Jie-wei Qiu, Hui-juan Wu, Xiao-dong Zhang, Bei Onco Targets Ther Original Research BACKGROUND: Primary pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare subtype of non-small cell lung cancer (NSCLC), and no effective treatments have been defined for advanced disease. Programmed cell death-ligand 1 (PD-L1) is expressed in a group of cancers that may be suitable targets for specific immunotherapy. METHODS: This study investigated the expression and clinical value of PD-L1 in pulmonary LELC. Seventy-nine patients with pulmonary LELC were investigated. Paraffin-embedded tumor sections were stained with PD-L1 antibody. Correlations of PD-L1 expression with clinicopathologic parameters and outcomes were analyzed. RESULTS: Fifty patients (63.3%) were PD-L1 positive. The 3-year and 5-year progression-free survival (PFS) rate was 76.0% and 68.0%, respectively, and the 3-year and 5-year overall survival (OS) rate was 88.0% and 79.0%, respectively. Kaplan–Meier analysis revealed that patients with positive PD-L1 expression had longer PFS and OS than those with negative PD-L1 expression (P=0.019 and P=0.042, respectively). In a multivariate Cox regression model including age, tumor size, stage, and PD-L1 expression status, the latter three factors were found to be independent predictors of PFS (P=0.023, P=0.000, and P=0.009, respectively), but only stage was found to be an independent factor for OS (P=0.007), and PD-L1 expression status showed a trend to be independently correlated with OS (P=0.080). CONCLUSION: Our results showed that a large proportion of patients with pulmonary LELC had positive expression of PD-L1, supporting the potential use of anti-PD-1/PD-L1-targeted therapies in this distinct type of NSCLC. Dove Medical Press 2015-06-15 /pmc/articles/PMC4474388/ /pubmed/26109869 http://dx.doi.org/10.2147/OTT.S84234 Text en © 2015 Jiang et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Jiang, Li Wang, Liang Li, Peng-fei Zhang, Xin-ke Chen, Jie-wei Qiu, Hui-juan Wu, Xiao-dong Zhang, Bei Positive expression of programmed death ligand-1 correlates with superior outcomes and might be a therapeutic target in primary pulmonary lymphoepithelioma-like carcinoma |
title | Positive expression of programmed death ligand-1 correlates with superior outcomes and might be a therapeutic target in primary pulmonary lymphoepithelioma-like carcinoma |
title_full | Positive expression of programmed death ligand-1 correlates with superior outcomes and might be a therapeutic target in primary pulmonary lymphoepithelioma-like carcinoma |
title_fullStr | Positive expression of programmed death ligand-1 correlates with superior outcomes and might be a therapeutic target in primary pulmonary lymphoepithelioma-like carcinoma |
title_full_unstemmed | Positive expression of programmed death ligand-1 correlates with superior outcomes and might be a therapeutic target in primary pulmonary lymphoepithelioma-like carcinoma |
title_short | Positive expression of programmed death ligand-1 correlates with superior outcomes and might be a therapeutic target in primary pulmonary lymphoepithelioma-like carcinoma |
title_sort | positive expression of programmed death ligand-1 correlates with superior outcomes and might be a therapeutic target in primary pulmonary lymphoepithelioma-like carcinoma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4474388/ https://www.ncbi.nlm.nih.gov/pubmed/26109869 http://dx.doi.org/10.2147/OTT.S84234 |
work_keys_str_mv | AT jiangli positiveexpressionofprogrammeddeathligand1correlateswithsuperioroutcomesandmightbeatherapeutictargetinprimarypulmonarylymphoepitheliomalikecarcinoma AT wangliang positiveexpressionofprogrammeddeathligand1correlateswithsuperioroutcomesandmightbeatherapeutictargetinprimarypulmonarylymphoepitheliomalikecarcinoma AT lipengfei positiveexpressionofprogrammeddeathligand1correlateswithsuperioroutcomesandmightbeatherapeutictargetinprimarypulmonarylymphoepitheliomalikecarcinoma AT zhangxinke positiveexpressionofprogrammeddeathligand1correlateswithsuperioroutcomesandmightbeatherapeutictargetinprimarypulmonarylymphoepitheliomalikecarcinoma AT chenjiewei positiveexpressionofprogrammeddeathligand1correlateswithsuperioroutcomesandmightbeatherapeutictargetinprimarypulmonarylymphoepitheliomalikecarcinoma AT qiuhuijuan positiveexpressionofprogrammeddeathligand1correlateswithsuperioroutcomesandmightbeatherapeutictargetinprimarypulmonarylymphoepitheliomalikecarcinoma AT wuxiaodong positiveexpressionofprogrammeddeathligand1correlateswithsuperioroutcomesandmightbeatherapeutictargetinprimarypulmonarylymphoepitheliomalikecarcinoma AT zhangbei positiveexpressionofprogrammeddeathligand1correlateswithsuperioroutcomesandmightbeatherapeutictargetinprimarypulmonarylymphoepitheliomalikecarcinoma |